Wilson's disease
ICD-10 E83.0 · ICD-11 5C64.00

Decompensated Liver Cirrhosis in Wilson's Disease: When Chelation Therapy Has Not Worked

In Wilson's disease presenting with decompensated cirrhosis and no hepatic encephalopathy, chelation therapy is the initial medical approach. When the required improvement in liver synthetic function is not achieved within the expected timeframe, a clearly defined next management step applies.

Clinical Scenario
Wilson's disease with decompensated cirrhosis, in the absence of hepatic encephalopathy. Patients in this setting may respond to medical therapy — typically after more than three months — but concurrent evaluation for liver transplantation is indicated from the outset.
Previous Line — Goals Not Reached
Prior therapy: Chelation therapy (as monotherapy or as combination therapy with D-penicillamine or trientine together with zinc).

Failure condition: Improvement in prothrombin time was not seen after the minimum expected period, or normalisation had not occurred within the expected window of three months to one year. This protocol describes the next step after that failure.
Next Step — Partial Overview
At this stage, the evidence-based approach centres on liver transplantation. Certain additional interventions may be used as a bridge while transplantation is being arranged — the full structured protocol specifies the conditions and options.
Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jhep.2024.11.007

Patients with decompensated cirrhosis in WD may respond to medical therapy, usually after >3 months of treatment, but they should be concomitantly evaluated for LT (LoE 3, strong recommendation, strong consensus).

Essentially, all patients with WD and decompensated chronic liver disease who fail to respond to or tolerate medical therapy should be considered promptly for transplantation.

Case series and small observational studies suggest that dialysis, plasmapheresis, albumin dialysis and high-volume plasma exchange can be considered as bridging therapies to LT in patients with WD ALF, especially once excess copper is detectable within the plasma.

View source ↗